

Sorafenib TARGET

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

ADJUSTMENTS

Quality of life

No QoL benefit

Serious and disabling adverse effects

Other adjustments

Sorafenib TARGET

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: Patients with advanced RCC who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy

Experimental Arm: Sorafenib

Control Arm: Placebo

